Generic Name and Formulations:
Propylthiouracil 50mg; scored tabs; contains docusate sodium.
Various generic manufacturers
Indications for Propylthiouracil:
Give in 3 equally divided doses every 8hrs. Initially 300mg/day. Severe conditions: initially 400mg/day; max 900mg/day. Maintenance: 100–150mg/day.
Give in 3 equally divided doses every 8hrs. <6yrs: not recommended. ≥6yrs: initially 50mg/day; may upward titrate based on response, TSH, and free T4 levels.
Should be reserved for those intolerant to methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments. Risk of severe liver injury and acute liver failure. Monitor for signs of hepatic dysfunction esp. in the 1st 6 months of therapy; discontinue if occur and obtain LFTs and ALT/AST levels. Discontinue if agranulocytosis, aplastic anemia, ANCA-positive vasculitis, hepatitis, interstitial pneumonitis, fever, or exfoliative dermatitis is suspected. Monitor thyroid function periodically, prothrombin time esp. before surgical procedures. Pregnancy (Cat.D). Nursing mothers.
May potentiate anticoagulants. Caution with other drugs that may cause agranulocytosis. May need to reduce doses of beta-blockers, digitalis glycosides, theophylline at euthyroid state.
Rash, urticaria, GI upset, arthralgia, paresthesia, taste loss/perversion, hair loss, myalgia, headache, drowsiness, edema, vertigo, jaundice, blood dycrasias, lupus-like syndrome, drug fever, hepatitis, hypoprothrombinemia.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|